Mondego Bio

PTPN2 Inhibitors for Cancer Immunotherapy

Cantanhede, Portugal · Founded 2025 · $22.3M raised

Headquarters
Cantanhede
Employees
11–50
Founded
2025
Business Model
B2B
Total Funding
$22.3M
Last Round
$2.3M Pre-SeedSep 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Mondego Bio is a Portuguese biotechnology company headquartered at Biocant, Portugal's main biotech park, developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors as a novel immuno-oncology therapy with improved safety and tolerability. Founded in March 2025 by investment firms Biovance Capital, OrbiMed, and Torrey Pines Investment, the company advances lead programs originally developed at Eilean Therapeutics, targeting enhanced IFN-gamma signaling through the JAK-STAT pathway. In September 2025, Mondego Bio closed a Series A round led by Biovance Capital with co-investors OrbiMed and Torrey Pines.

Summary

Mondego Bio is a Biotech company based in Cantanhede, Portugal, founded in 2025. It has raised $22.3M in total across 2 rounds, most recently a $2.3M Pre-Seed round in Sep 2025. Investors include Biovance Capital, OrbiMed and Torrey Pines Investment.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Pre-seedPre-SeedSep 2025
$2.3M

Sign up to see all 2 events

Funding: Pre-Seed through Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
Avenzo

Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...

San Diego, United States1–10Biotech, Oncology
Series BTotal funding$832.0MSep 2025
Bicycle TherapeuticsIPO

Novel bicyclic peptides and drug conjugates for cancer

Cambridge, United States201–500Biotech, Oncology
Private EquityTotal funding$607.0MJan 2024
ParexelAcquired

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...

Raleigh, United States10001+Biotech
Private EquityTotal funding$5.0BJun 2017
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Mondego Bio on Indexed.vc
<a href="https://indexed.vc/companies/mondego-bio"><img src="https://indexed.vc/api/badge/company/mondego-bio" alt="Mondego Bio on Indexed.vc" width="260" height="76" /></a>